Threshold glufosfamide enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Threshold begins Phase III pancreatic cancer trial for glufosfamide following special protocol assessment agreement from FDA, the firm announces Sept. 13. The 306-patient study will randomize patients with metastatic pancreatic cancer refractory to first-line treatment to receive glufosfamide every three weeks on top of best supportive care or BSC alone. "As part of our registration and approval strategy, we are also planning to initiate, before the end of 2004, a Phase II clinical trial of glufosfamide in combination with Gemzar for the first-line treatment of inoperable locally advanced or metastatic pancreatic cancer," the firm says...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.